EDITORIAL
A driving force to accelerate drug development
Fostering academic clinical research is one of the ESMO’s priorities, and artificial intelligence may be a major driver
RARE CANCERS & SARCOMA
Why clinical practice guidelines matter even more in rare cancers
A recent EURACAN survey highlights a high uptake of recommendations from medical oncologists, potentially leading to improved patients’ survival
Ozekibart added to chemotherapy demonstrates robust activity in relapsed/refractory Ewing sarcoma
Preliminary data on the tetravalent DR5 agonist indicate strong and durable responses with a manageable safety profile
New immunotherapy option emerges for low-risk gestational trophoblastic neoplasia
Adding first-line checkpoint inhibition to standard treatment shows promise to improve response in women
AI & DIGITAL ONCOLOGY
Research unlocks insights into lung cancer evolution from electronic medical records
A domain-specific natural language processing (NPL) pipeline showed strong performance in extracting clinically meaningful information from diverse clinical documents of patients with non-small cell lung cancer
Trustworthy and explainable AI – a key to equitable oncology?
Mitigating research biases by rigorous data analysis and validation can pave the way for a wider adoption of artificial intelligence in cancer care
Study supports radiomics in predicting immunotherapy effectiveness in advanced NSCLC
In a real-world study, multimodal artificial intelligence models outperform PD-L1 across key endpoints
LATEST FROM ESMO
How to close the age gap in clinical cancer research?
From geriatric assessment to artificial intelligence, an ESMO/SIOG paper highlights effective strategies to improve the representation of older patients in clinical trials
Structured exercise enters ESMO guidelines for colon cancer as recommended treatment
The update reflects survival benefits of post-diagnosis exercise in stage II–III colon cancer as recently reported in the CHALLENGE study
The first ESMO guidance for AI-based biomarkers
In a newly released framework paper, ESMO defines criteria for assessing and implementing AI-based biomarkers in oncology
OPINIONS
Redesigning oncology clinical trials with agentic AI
Jorge Reis-Filho
From bispecific to multispecific antibodies: a highly promising field
Nina Weisser
The challenge of undifferentiated sarcomas
Pawel Sobczuk
Sex and gender are key for precision oncology and benefit all patients
Berna Özdemir
The power of dual-layer genomics in precision oncology
Umberto Malapelle
OPINIONS
Redesigning oncology clinical trials with agentic AI
Jorge Reis-Filho
From bispecific to multispecific antibodies: a highly promising field
Nina Weisser
The challenge of undifferentiated sarcomas
Pawel Sobczuk
Sex and gender are key for precision oncology and benefit all patients
Berna Özdemir
The power of dual-layer genomics in precision oncology
Umberto Malapelle